| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/100-1/300 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | GLIPR; RTVP1; CRISP7 |
| WB Predicted band size | 30 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Fusion protein of human GLIPR1 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于GLIPR1抗体的**示例参考文献**(注：以下内容为虚构示例，仅供格式参考，实际文献请通过学术数据库查询)：
---
1. **文献名称**：*GLIPR1 as a Biomarker in Prostate Cancer: Expression Analysis Using Monoclonal Antibodies*
**作者**：Xie, Y., et al.
**摘要**：本研究开发了针对GLIPR1蛋白的单克隆抗体，并验证了其在前列腺癌组织中的高表达。结果显示，GLIPR1可能作为肿瘤抑制因子，其表达缺失与癌症进展相关，抗体可用于临床样本的免疫组化检测。
2. **文献名称**：*Targeting GLIPR1 in Glioblastoma: Therapeutic Antibody Development and Functional Studies*
**作者**：Li, H., et al.
**摘要**：通过制备人源化抗GLIPR1抗体，本研究证明其在胶质母细胞瘤模型中可诱导肿瘤细胞凋亡，并抑制肿瘤生长。抗体与化疗联用显示出协同治疗效果。
3. **文献名称**：*GLIPR1-Mediated DNA Damage Response in Ovarian Cancer: Role of Polyclonal Antibodies in Mechanistic Analysis*
**作者**：Smith, J., et al.
**摘要**：利用多克隆抗体研究GLIPR1在卵巢癌细胞DNA损伤修复中的作用，发现其通过调控ATM/ATR信号通路影响化疗敏感性，抗体用于蛋白定位及相互作用分析。
4. **文献名称**：*GLIPR1 Antibody-Drug Conjugates for Targeted Cancer Therapy*
**作者**：Wang, L., et al.
**摘要**：报道了一种新型抗GLIPR1抗体-药物偶联物(ADC)，在肺癌异种移植模型中显著抑制肿瘤生长，抗体特异性靶向肿瘤细胞并减少脱靶毒性。
---
**提示**：实际文献可通过PubMed、Google Scholar等平台以关键词“GLIPR1 antibody”、“GLIPR1 therapeutic target”检索。真实研究多聚焦于GLIPR1在肿瘤抑制、表观遗传调控及免疫治疗中的应用。
The Glioma Pathogenesis-Related Protein 1 (GLIPR1), also known as GLIPR or RTVP-1. is a member of the CAP (cysteine-rich secretory proteins, antigen 5. and pathogenesis-related 1 proteins) superfamily. Initially identified for its upregulated expression in glioblastoma, GLIPR1 is a secreted protein implicated in diverse cellular processes, including proliferation, apoptosis, and differentiation. Structurally, it contains a conserved CAP domain linked to lipid-binding and membrane-interaction functions. GLIPR1 exhibits dual roles in cancer, acting as a tumor suppressor in gliomas and prostate cancer by promoting apoptosis and inhibiting invasiveness, while paradoxically supporting tumor progression in other contexts, such as melanoma or osteosarcoma, through pro-survival signaling. Its expression is often epigenetically silenced via promoter hypermethylation in prostate cancer, correlating with disease progression.
GLIPR1 antibodies are critical tools for studying its expression patterns, localization, and regulatory mechanisms in both normal and pathological states. They enable detection via Western blot, immunohistochemistry, and flow cytometry, aiding research into GLIPR1's role in cancer biology, neurodevelopment, and immune modulation. Therapeutic applications are also explored, including antibody-mediated targeting of GLIPR1 in cancers or leveraging its immunostimulatory properties for vaccine development. Additionally, GLIPR1 antibodies may serve as diagnostic or prognostic biomarkers, particularly in malignancies marked by dysregulated GLIPR1 expression. Ongoing studies focus on clarifying its context-dependent functions and therapeutic potential.
×
